Patent · US Active

Controlling the activity of growth factors, particularly TGF-β, in vivo

US10092891B2 · kind B2 · utility

0Cited by
5References
9Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 25, 2014
Grant dateOct 9, 2018
Priority date—
Expiry dateMar 5, 2036

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K47/6923
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

TGF-β growth factor and its latent complex are conjugated to magnetic micro- or nanoparticles and to magnetic micro- or nanodiscs. By exposing the resulting conjugates to magnetic fields, the TGF-β growth factor can be released from its latent complex in vivo, potentially making it useful in tissue engineering and regenerative medicine. And by exposing a conjugate of TGF-β growth factor and a magnetic particle to a sufficiently strong, radiofrequency magnetic field, the TGF-β growth factor can be denatured and thereby deactivated, potentially making it possible to avoid triggering tumorigenesis, atherosclerosis, fibrotic disease, and cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.